Pacira Biosciences, Inc. (PCRX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2026. Pacira BioSciences, Inc. is a biopharmaceutical company focused on non-opioid pain therapies. Its commercial portfolio includes EXPAREL (postsurgical pain), ZILRETTA (osteoarthritis knee pain), and iovera (cryoanalgesia device). The company is advancing clinical programs for PCRX-201 (gene therapy for knee OA) and PCRX-2002 (long-acting ropivacaine).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $177.4 million | $168.9 million |
| Net Income | $2.9 million | $4.8 million |
| Diluted EPS | $0.07 | $0.10 |
| Operating Cash Flow | $25.7 million | $35.5 million |
| Cash & Investments | $202.2 million | $283.6 million (Cash only) |
| Long-Term Debt | $367.7 million | $372.2 million |
| Gross Margin | 79% | 80% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5% year-over-year. EXPAREL sales rose 5% (driven by 7% volume growth), ZILRETTA sales increased 15% (11% volume growth), and iovera sales grew 21%.
- Profitability: Net income decreased 40% to $2.9 million, primarily due to a $4.4 million gain on GQ Bio investment in Q1 2025 that did not recur, and lower interest income.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 8% to $93.9 million. Research and Development (R&D) expenses rose 11% to $28.1 million, driven by clinical trial enrollment and HCAd platform investment.
- Debt Management: The company repaid $5.0 million on its Revolving Credit Facility. The 2025 Convertible Notes matured and were settled in Q3 2025; the 2029 Notes remain outstanding at $287.5 million principal.
- Share Repurchases: The company repurchased 2.24 million shares for $50.4 million under its $300 million program, leaving approximately $100 million remaining.
Outlook, Risks, and Unusual Items
- Tariff Exposure: A U.S. Presidential Order issued April 2, 2026, imposes tariffs on pharmaceutical products from the EU (15%) and UK (10%). Pacira expects these to apply to APIs and finished goods for EXPAREL and ZILRETTA, potentially increasing costs.
- Legal Proceedings:
- Generic Litigation: The company settled patent infringement suits with eVenus ANDA Filers in Q1 2025 (costing $7.0 million). New Paragraph IV certifications were received in late 2025 from WhiteOak and Qilu regarding EXPAREL; litigation is ongoing.
- RDF Royalty Dispute: A court ruled in Pacira's favor regarding royalty obligations to the Research Development Foundation, resulting in a $28.3 million recovery in Q3 2025. An appeal is pending.
- Strategic Partnerships: Entered a partnership with LG Chem for EXPAREL in Asia-Pacific (Jan 2026) and a co-promotion agreement with J&J MedTech for ZILRETTA in the U.S. (July 2025).
- Clinical Milestones: Enrollment concluded for the ZILRETTA shoulder OA Phase 3 study (results expected later in 2026). Part A of the PCRX-201 Phase 2 ASCEND study is complete; Part B is expected to initiate mid-2026.
Investor Verification Checklist
- Tariff Impact Analysis: Verify the specific cost pass-through mechanisms and margin impact of the new April 2026 tariffs on UK/EU sourced products.
- Generic Defense Costs: Monitor legal expense trends related to the new WhiteOak and Qilu EXPAREL litigation.
- Share Repurchase Execution: Track the pace of the remaining $100 million repurchase authorization and its impact on share count.
- Contingent Consideration: Review the fair value adjustments to the Flexion Acquisition contingent liability ($15.8 million), which fluctuates based on sales forecasts.
- Cash Burn vs. Revenue: Assess the sustainability of operating cash flows given the 28% increase in product development R&D expenses.